Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma

Hongyu Zhang, MD PhD, Jia Feng, MD PhD, Wenli Zhang, MD, Qi Chen, PhD, Yuanzhen Cao, Kevin Pinz, Fang Liu, MD PhD, Yu Ma, Masayuki Wada, PhD, Yupo Ma, MD PhD

Blood (2019) 134 (Supplement_1): 2881.

https://doi.org/10.1182/blood-2019-122789

Published: 2019

Journal Articles

Diagnostic Challenges in the Era of Genomic Sequencing and Newborn Screening

Jennifer Puck, MD

Blood (2017) 130 (Supplement 1): SCI-30.

https://doi.org/10.1182/blood.V130.Suppl_1.SCI-30.SCI-30

Published: 2017

Journal Articles

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

Tycel Phillips, MD, Rod Ramchandren, MD, Michael S Wertheim, MD, Martin E Gutierrez, MD, William J Edenfield, MD, Fitzroy Dawkins, MD, Doug J DeMarini, Li Zhou, PhD, Swamy Yeleswaram, PhD, Robert C Newton, PhD, Xuejun Chen, PhD, Andres Forero-Torres, MD

Blood (2016) 128 (22): 4195.

https://doi.org/10.1182/blood.V128.22.4195.4195

Published: 2016

Journal Articles

Mexican Patient with Refractory Mycosis Fungoides Successfully Treated with Pralatrexate at Low Doses: Case Report

Jose R Lopez, Hematologist

Blood (2015) 126 (23): 5068.

https://doi.org/10.1182/blood.V126.23.5068.5068

Published: 2015

Journal Articles

Profound Hypereosinophilia Secondary to Sezary Syndrome

Ardy Davarifar, MD, Ricklie Julian, MD, Pareek Vipul, MD, Emrullah Yilmaz, MD, Amit Verma, MD

Blood (2015) 126 (23): 5053.

https://doi.org/10.1182/blood.V126.23.5053.5053

Published: 2015

Journal Articles

Clinical Features of Folliculotrophic Mycosis Fungoides

Wang Casey, MD, Rakhshandra Talpur, MD, Silvia Alberti-Violetti, MD, Iris Wieser, MD, Casey Tran, Madeleine Duvic, MD

Blood (2015) 126 (23): 1488.

https://doi.org/10.1182/blood.V126.23.1488.1488

Published: 2015

Journal Articles

Immunological Derangement in Follicular Lymphoma Patients Developing Severe Side Effects during Treatment with PI3K Inhibitors

Marina Motta, MD, Marco Chiarini, MSC, Marta Petullà, PharmD, Claudia Ghidini, BSC, Marion Vaglio Tessitore, BSC, Viviana Giustini, MSC, Chiara Pagani, MD, Antonella Anastasia, MD, Samantha Ferrari, MD, Alessandra Tucci, Luisa Imberti, MD, Giuseppe Rossi, MD

Blood (2015) 126 (23): 1531.

https://doi.org/10.1182/blood.V126.23.1531.1531

Published: 2015

Journal Articles

Sézary Syndrome: Clinicopathological and Immunophenotypical Characteristics and Outcomes

Christa Roe, RN, BS, OCN, Jennifer Rock-Klotz, BA, Elyce Turba, RN, MSN, OCN, Christopher Rodriguez Salamanca, PA, Janice Bennett, MS, ARNP-C, Farrah Farquharson, PA, Sem Bastien, MS, ARNP-C, Barbara Williams, RN, BS, OCN, Rebecca Levy, MS, ARNP-C, Yibo Li, BS, Michael Montejo, MD, Ernesto Ayala, MD, Pedro Horna, MD, Lewis F Glass, MD, Rami S. Komrokji, MD, Lubomir Sokol, MD PhD

Blood (2015) 126 (23): 1546.

https://doi.org/10.1182/blood.V126.23.1546.1546

Published: 2015

Journal Articles

Omenn syndrome associated with a functional reversion due to a somatic second-site mutation in CARD11 deficiency

Sebastian Fuchs, Anne Rensing-Ehl, Ulrich Pannicke, Myriam R. Lorenz, Paul Fisch, Yogesh Jeelall, Jan Rohr, Carsten Speckmann, Thomas Vraetz, Susan Farmand, Annette Schmitt-Graeff, Marcus Krüger, Brigitte Strahm, Philipp Henneke, Anselm Enders, Keisuke Horikawa, Christopher Goodnow, Klaus Schwarz, Stephan Ehl

Blood (2015) 126 (14): 1658–1669.

https://doi.org/10.1182/blood-2015-03-631374

Published: 2015

Includes: Supplemental data

Journal Articles

A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

Beth Christian, MD, John Kuruvilla, MD, Sonali Smith, MD, Pierluigi Porcu, MD, Amy S. Ruppert, MAS, John C. Byrd, MD, Michael R. Grever, MD, Kristie A. Blum, MD

Blood (2014) 124 (21): 4476.

https://doi.org/10.1182/blood.V124.21.4476.4476

Published: 2014

Journal Articles

Bortezomib and Methotrexate Interfere with the DNA Repair Signaling Transduction Pathways and Induce Apoptosis in Cutaneous T-Cell Lymphoma

Vassiliki Mpakou, Evangelia Papadavid, Evi Konsta, Vikentiou Murofora, Frieda Kontsioti, Sotiris Papageorgiou, Dikea-Eleni Ioannidou, MD, Eleni Bazani, Christina Economopoulou, MD, Diamantina Vasilatou, Maria Atta, MD, Nikos Papanikolaou, Christoforos Roubakis, Panagiotis Tsirigotis, MD, Christina Antoniou, Dimitris Rigopoulos, George Dimitriadis, Vassiliki Pappa, MD

Blood (2014) 124 (21): 5232.

https://doi.org/10.1182/blood.V124.21.5232.5232

Published: 2014

Journal Articles

Integrated Genome Sequencing Reveals Frequent Loss of Function Alterations of ARID1A and Other Epigenetic Modifiers in Sezary Syndrome

Mark Kiel, MDPhD, Anagh A Sahasrabuddhe, PhD, Thiru Velusamy, PhD, Fuzon Chung, PhD, Nathanael G. Bailey, MD, Bryan L Betz, PhD, David W Bahler, MD PhD, Roberto N. Miranda, MD, L. Jeffrey Medeiros, MD, Megan S Lim, MD PhD, Kojo S.J. Elenitoba-Johnson, MD

Blood (2014) 124 (21): 706.

https://doi.org/10.1182/blood.V124.21.706.706

Published: 2014

Journal Articles

Whole Exome Sequencing and Analysis Of Mutations In Sézary Syndrome

David A. Wheeler, PhD, Lui Xi, Xiao Ni, MD, PhD, Misha Koshelev, MD, PhD, Jennifer Drummond, Donna M. Muzny, Xiang Zhang, MD, MS, Madeleine Duvic, MD

Blood (2013) 122 (21): 2558.

https://doi.org/10.1182/blood.V122.21.2558.2558

Published: 2013

Journal Articles

RP6530, a Dual PI3Kδ/γ Inhibitor, Attenutates AKT Phosphorylation and Induces Apoptosis In Primary Cutaneous T Cell Lymphoma (CTCL) Cells

Julia Lewis, Ph.D, Michael Girardi, MD, FAAD, Swaroop Vakkalanka, PhD, Srikant Viswanadha, Ph.D., Francesco Bertoni, MD

Blood (2013) 122 (21): 4418.

https://doi.org/10.1182/blood.V122.21.4418.4418

Published: 2013

Journal Articles

Severe Adverse Skin Reaction Used For Sclerodermatous Chronic Graft Versus Host Disease Of The Skin

Caroline Hamm, MD, FRCPC, Sindu M. Kanjeekal, MD, FRCPC, David Shum, Tarek Elfiki, John Mathews

Blood (2013) 122 (21): 5417.

https://doi.org/10.1182/blood.V122.21.5417.5417

Published: 2013

Journal Articles

Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Carlos Guillermo Romo, MD, Alfonso Quintas-Cardama, MD, Elias Jabbour, MD, Marylou Cardenas-Turanzas, MD, Dr PH, Sherry Pierce, Mary Joy Liboon, Evguenia Gachimova, Tapan M. Kadia, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 4019.

https://doi.org/10.1182/blood.V122.21.4019.4019

Published: 2013

Journal Articles

Anayisis of Chromosomal Alterations by Array-Based Comparative Genomic Hybridization in 25 Patients with Sézary Syndrome.

Giorgia Saporiti, MD, Laura Corti, MS, PhD, Francesco Onida, MD, Daniele Fanoni, MS, Luigia Venegoni, MS, Elisabetta Caprini, PhD, Cristina Cristofoletti, PhD, Giandomenico Russo, MD, PhD, Agostino Cortelezzi, MD, Emilio Berti, MD

Blood (2012) 120 (21): 2714.

https://doi.org/10.1182/blood.V120.21.2714.2714

Published: 2012

Journal Articles

Romidepsin in the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): The New York University Cancer Center Experience

Salvia Jain, MD, Kenneth B. Hymes, MD

Blood (2011) 118 (21): 4961.

https://doi.org/10.1182/blood.V118.21.4961.4961

Published: 2011

Journal Articles

Effect of Denileukin Diftitox on Pruritus and Other Skin-Related Symptoms Vs Placebo In Patients with Cutaneous T-Cell Lymphoma

Lauren Pinter-Brown, MD, Anna Kozlovski

Blood (2010) 116 (21): 4922.

https://doi.org/10.1182/blood.V116.21.4922.4922

Published: 2010

Journal Articles

Response Rate of 16% and High Incidence of Adverse Events In Placebo-Treated Patients with CD25 Assay-Positive Cutaneous T-Cell Lymphoma (CTCL): An Analysis of Patient Characteristics and Predictors of Response

Miles Prince, MD, FRACP, FRCPA, Madeleine Duvic, MD, Ann Martin, MD, Wolfram Sterry, MD, Chalid Assaf, MD, David Straus, MD

Blood (2010) 116 (21): 4158.

https://doi.org/10.1182/blood.V116.21.4158.4158

Published: 2010

NARROW

First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma

Diagnostic Challenges in the Era of Genomic Sequencing and Newborn Screening

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

Mexican Patient with Refractory Mycosis Fungoides Successfully Treated with Pralatrexate at Low Doses: Case Report

Profound Hypereosinophilia Secondary to Sezary Syndrome

Clinical Features of Folliculotrophic Mycosis Fungoides

Immunological Derangement in Follicular Lymphoma Patients Developing Severe Side Effects during Treatment with PI3K Inhibitors

Sézary Syndrome: Clinicopathological and Immunophenotypical Characteristics and Outcomes

Omenn syndrome associated with a functional reversion due to a somatic second-site mutation in CARD11 deficiency

A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

Bortezomib and Methotrexate Interfere with the DNA Repair Signaling Transduction Pathways and Induce Apoptosis in Cutaneous T-Cell Lymphoma

Integrated Genome Sequencing Reveals Frequent Loss of Function Alterations of ARID1A and Other Epigenetic Modifiers in Sezary Syndrome

Whole Exome Sequencing and Analysis Of Mutations In Sézary Syndrome

RP6530, a Dual PI3Kδ/γ Inhibitor, Attenutates AKT Phosphorylation and Induces Apoptosis In Primary Cutaneous T Cell Lymphoma (CTCL) Cells

Severe Adverse Skin Reaction Used For Sclerodermatous Chronic Graft Versus Host Disease Of The Skin

Patterns Of Non-Hematological Adverse Effects In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Treated With Ponatinib – Experience At a Single Institution

Anayisis of Chromosomal Alterations by Array-Based Comparative Genomic Hybridization in 25 Patients with Sézary Syndrome.

Romidepsin in the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): The New York University Cancer Center Experience

Effect of Denileukin Diftitox on Pruritus and Other Skin-Related Symptoms Vs Placebo In Patients with Cutaneous T-Cell Lymphoma

Response Rate of 16% and High Incidence of Adverse Events In Placebo-Treated Patients with CD25 Assay-Positive Cutaneous T-Cell Lymphoma (CTCL): An Analysis of Patient Characteristics and Predictors of Response

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only